Европейская академия естественных наук Hannover E.V.

Xi-Yong Yu

Dr. Xi-Yong Yu is currently a Chair Professor and the Dean of School of Pharmaceutical Sciences and the Director of Institute for Molecular & Clinical Pharmacology at Guangzhou Medical University, and also serve as the Director of the Key Laboratory for Drug Research and Evaluation of Thoracic Disease Treatment at National Medical Products Administration of China, the Director of the Joint Laboratory of Guangdong-Hong Kong-Macao

Guangdong-Hong Kong- Macao Greater Bay Area Universities, the Director of the Key Laboratory of Molecular Target and Clinical Pharmacology in

Guangdong Province. He had studied abroad at the University of Hong Kong (2000-2001) and the Baylor College of Medicine in the United States (2002-2003) to engage in postdoctoral research.

Dr. Yu received his B.S. degree in clinical medicine from Hubei University of Science & Technology (1981-1986), M.Sci. degree in clinical pharmacology from Sun Yet-Sen University (1986-1989), Ph.D. degree in cardiovascular pharmacology from Nanjing Medical University (1995-1998), China. He had studied abroad at the University of Hong Kong (2000-2001) and the Baylor College of Medicine in the United States (2002-2003) to engage in postdoctoral research.

Dr. Yu mainly focuses on the expand research on pulmonary heart disease, and established three emerging interdisciplinary fields: molecular clinical pharmacology, epigenetic pharmacology, and molecular pharmaceutical biology. He has undertaken 1 key special project of the National ^{Key R&D Program “Strategic Scientific and Technological Innovation Cooperation” (Chief Scientist), 7 National Natural Science Funds (including 3 key}

projects), 3 National 973 Projects (including 1 independent project), and 1 national teaching reform project. He has presided over and completed more than 60 phase I clinical trials and bioequivalence (BE) trials for new drugs, and more than 20 preclinical studies for novel medicines. He has published more than 600 papers in academic journals at home and abroad, including 230 SCI papers (more than 70 SCI papers with IF>10). He has won 5 Science and Technology Awards of the Guangdong Provincial Government (including 2 first prizes), 5 Scientific and Technological Progress Awards of the Guangdong Provincial Medical and Health (including 3 first prizes), the first prize of scientific and technological achievements of the New Century China Innovation,

and the China Innovation Award for Industry-University-Research Collaboration. He has also obtained more than 30 domestic and foreign invention patents and "Gold Award" of the Geneva International Invention Prize. He was awarded the Special Government Allowance of the State Council of China (2005), the Most Beautiful Science and Technology Scientist of Guangzhou (2023), and was selected into the World's Top 2% Scientists List in the field of pharmacy jointly published by Stanford University and Elsevier, as well as the list of 100,000 top scientists in various fields around the world.

Professor Yu's main social positions include: Vice President of the Chinese Pharmacological Society (a national first-level society), Chairman of the Epigenetics Pharmacology Committee of the Chinese Pharmacological Society (a national second-level society), Chairman/Honorary Chairman/Chief Supervisor of the Guangdong Pharmacological Society, Chairman of the South China Biomedical Innovation R&D Technology Service Alliance, Chairman /Honorary Chairman of the Cardiovascular Committee of the Chinese Pathophysiological Society, and Vice Chairman of the International Society of Heart Research (ISHR) China Branch. He is now a leading figure in epigenetic pharmacology in China.

 

вверх

Энциклопедия ЕАЕН

 ¦  Impressum  ¦  Контакт